The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology have updated their 2013 molecular analysis guideline for the selection of patients with lung cancer for TKI treatment, to include 18 new recommendations and 3 revisions to the existing guidance.
Osimertinib Nearly Doubles PFS, Receives Breakthrough Therapy Designation in Frontline Treatment of EGFR-Positive NSCLC
Pembrolizumab, Pemetrexed, and Platinum Chemotherapy Combination Shows Improved OS and PFS in Patients with Metastatic Nonsquamous NSCLC
In the pivotal phase 3 KEYNOTE-189 trial of pembrolizumab (Keytruda) combined with pemetrexed and cisplatin or carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small-cell lung cancer, the regimen showed significant improvements in overall survival and progression-free survival.
Although crizotinib is the standard of care for the first-line treatment of patients with ALK-positive non–small-cell lung cancer, disease progression occurs in most crizotinib-treated patients, often calling for the use of second-generation ALK inhibitors such as alectinib, brigatinib, and ceritinib, among other treatment strategies.
Results from a phase 2 trial of lorlatinib, an investigational, next-generation tyrosine kinase inhibitor, showed efficacy in treating lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced non–small-cell lung cancer, including those who have been heavily pretreated.
Updated data from the phase 2 ALTA trial continue to support the efficacy and tolerability of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK), in patients with locally advanced or metastatic ALK-positive non–small-cell lung cancer (NSCLC) who have progressed while using crizotinib.
Until the expanded approval of afatinib, no targeted treatment options were available for patients with non–small-cell lung cancer (NSCLC) who harbored rare, nonresistant EGFR mutations, such as S768I, L861Q, and G719X. Among oral tyrosine kinase inhibitors approved for use in EGFR mutation–positive NSCLC, afatinib now offers the broadest first-line indication.
Page 3 of 18
Results 21 - 30 of 180
Results 21 - 30 of 180